Antigenic Regions Within the Hepatitis C Virus Envelope 1 and Non-structural Proteins: Identification of an IgG3-restricted Recognition Site with the Envelope 1 Protein

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1993 Mar 1

PMID 7680297

Citations 11

Authors

M Sallberg

U Ruden

B Wahren

L O Magnius

Affiliations

Soon will be listed here.

Abstract

Antibody binding to antigenic regions of hepatitis C virus (HCV) envelope 1 (E1; residues 183-380, E2/non-structural (NS) 1 (residues 380-437), NS1 (residues 643-690), and NS4 (1684-1751) proteins were assayed for 50 sera with antibodies to HCV (anti-HCV) and for 46 sera without anti-HCV. Thirty-four peptides, 18 residues long with an eight-amino acid overlap within each HCV region, were synthesized and tested with all 96 sera. Within the E region 183-380, the major binding site was located to residues 203-220, and was recognized by eight sera. Within the E2/NS1 region 380-437, the peptide covering residues 410-427 was recognized by two sera, and within the NS1 region 643-690, peptides covering residues 663-690 were recognized by four sera. Within the NS4 region 1684-1751, 27 sera were reactive to one or more of the NS4 peptides, and 21 out of these were reactive with peptide 1694-1711. One part of the major binding site could be located to residues 1701-1704, with the sequence Leu-Tyr-Arg-Glu. The IgG1, IgG3 and IgG4 subclasses were reactive with the five antigenic regions of HCV core, residues 1-18, 11-28, 21-38, 51-68 and 101-118. Reactivity to the major envelope site consisted almost exclusively of IgG3, and reactivity to the major site of NS4 consisted only of IgG1. Thus, a non-restricted IgG response to linear HCV-encoded binding sites was found to the core protein, whereas IgG subclass-restricted linear binding sites were found within the E1 protein, and within the NS4 protein.

Citing Articles

Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.

Walker M, Eltahla A, Mina M, Li H, Lloyd A, Bull R Viruses. 2020; 12(1).

PMID: 31936235 PMC: 7019651. DOI: 10.3390/v12010075.

Relationship between humoral response against hepatitis C virus and disease overcome.

Brakha C, Arvers P, Villiers F, Marlu A, Buhot A, Livache T Springerplus. 2014; 3:56.

PMID: 24516785 PMC: 3915053. DOI: 10.1186/2193-1801-3-56.

Clustering of rare peptide segments in the HCV immunome.

Stufano A, Capone G, Pesetti B, Polimeno L, Kanduc D Self Nonself. 2011; 1(2):154-162.

PMID: 21487517 PMC: 3065674. DOI: 10.4161/self.1.2.11391.

Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.

Meunier J, Russell R, Goossens V, Priem S, Walter H, Depla E J Virol. 2007; 82(2):966-73.

PMID: 17977972 PMC: 2224608. DOI: 10.1128/JVI.01872-07.

Restricted isotypic antibody reactivity to hepatitis C virus synthetic peptides in immunocompromised patients.

Devesa M, de Saez A, Leon G, Sirit F, Cosson C, Bermudez H Clin Diagn Lab Immunol. 1999; 6(2):279-81.

PMID: 10066669 PMC: 95702. DOI: 10.1128/CDLI.6.2.279-281.1999.

References

Skvaril F . IgG subclasses of anti-HBs antibodies in vaccinated and nonvaccinated individuals and in anti-HBs immunoglobulin preparations. Int Arch Allergy Appl Immunol. 1984; 73(4):330-7. DOI: 10.1159/000233493. View

Farci P, Alter H, Govindarajan S, Wong D, Engle R, Lesniewski R . Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992; 258(5079):135-40. DOI: 10.1126/science.1279801. View

Salberg M, Norder H, Weiland O, Magnius L . Immunoglobulin isotypes of anti-HBc and anti-HBe and hepatitis B virus (HBV) DNA elimination in acute hepatitis B. J Med Virol. 1989; 29(4):296-302. DOI: 10.1002/jmv.1890290414. View

Sallberg M, Norder H, Magnius L . Comparison of class and subclass distribution of antibodies to the hepatitis B core and B e antigens in chronic hepatitis B. J Med Virol. 1990; 30(1):1-6. DOI: 10.1002/jmv.1890300102. View

Weiner A, BRAUER M, Rosenblatt J, Richman K, Tung J, Crawford K . Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991; 180(2):842-8. DOI: 10.1016/0042-6822(91)90104-j. View

van der Poel C, Cuypers H, Reesink H, Weiner A, Quan S, Di Nello R . Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991; 337(8737):317-9. DOI: 10.1016/0140-6736(91)90942-i. View

Choo Q, Richman K, Han J, Berger K, Lee C, Dong C . Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991; 88(6):2451-5. PMC: 51250. DOI: 10.1073/pnas.88.6.2451. View

Chiba J, Ohba H, Matsuura Y, Watanabe Y, Katayama T, Kikuchi S . Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci U S A. 1991; 88(11):4641-5. PMC: 51721. DOI: 10.1073/pnas.88.11.4641. View

Sallberg M, Ruden U, Wahren B, Noah M, Magnius L . Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant. Mol Immunol. 1991; 28(7):719-26. DOI: 10.1016/0161-5890(91)90114-y. View

10.

Muraiso K, Hijikata M, Kato N, Shimotohno K, Okazaki N, Ohkoshi S . Detection of hepatitis C virus infection by enzyme-linked immunosorbent assay system using core protein expressed in Escherichia coli. Jpn J Cancer Res. 1991; 82(8):879-82. PMC: 5918576. DOI: 10.1111/j.1349-7006.1991.tb01914.x. View

11.

Cerino A, Mondelli M . Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies. J Immunol. 1991; 147(8):2692-6. View

12.

Chaudhary R, Maclean C . Evaluation of first- and second-generation RIBA kits for detection of antibody to hepatitis C virus. J Clin Microbiol. 1991; 29(10):2329-30. PMC: 270322. DOI: 10.1128/jcm.29.10.2329-2330.1991. View

13.

Sallberg M, Ruden U, Magnius L, Norrby E, Wahren B . Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett. 1991; 30(1):59-68. DOI: 10.1016/0165-2478(91)90090-w. View

14.

Mattsson L, Gutierrez R, Dawson G, Lesniewski R, Mushahwar L, Weiland O . Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in long-term-studied patients with posttransfusion hepatitis C. Scand J Gastroenterol. 1991; 26(12):1257-62. DOI: 10.3109/00365529108998622. View

15.

Okamoto H, Tsuda F, Machida A, Munekata E, Akahane Y, Sugai Y . Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis virus infection. Hepatology. 1992; 15(2):180-6. DOI: 10.1002/hep.1840150203. View

16.

Matsuura Y, Harada S, Suzuki R, Watanabe Y, Inoue Y, Saito I . Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells. J Virol. 1992; 66(3):1425-31. PMC: 240866. DOI: 10.1128/JVI.66.3.1425-1431.1992. View

17.

Ching W, Wychowski C, Beach M, Wang H, Davies C, Carl M . Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. Proc Natl Acad Sci U S A. 1992; 89(8):3190-4. PMC: 48831. DOI: 10.1073/pnas.89.8.3190. View

18.

Weiner A, Geysen H, Christopherson C, Hall J, Mason T, Saracco G . Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992; 89(8):3468-72. PMC: 48889. DOI: 10.1073/pnas.89.8.3468. View

19.

Sallberg M, Ruden U, Wahren B, Magnius L . Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J Clin Microbiol. 1992; 30(8):1989-94. PMC: 265429. DOI: 10.1128/jcm.30.8.1989-1994.1992. View

20.

Albert J, Franzen L, Jansson M, Scarlatti G, Kataaha P, Katabira E . Ugandan HIV-1 V3 loop sequences closely related to the U.S./European consensus. Virology. 1992; 190(2):674-81. DOI: 10.1016/0042-6822(92)90905-5. View